Prostate Cancer Treatment

Prostate cancer (PC) represents the most frequently diagnosed malignancy among men in 112 countries, ranking globally as the second most commonly diagnosed cancer and the fifth leading cause of cancer-related death in men. In 2022, an estimated 1.46 million new cases and 396,000 deaths were attributed to the disease, with a five-year relative survival rate of approximately 98% across all stages combined, falling to 38% once distant metastasis is present. Projections based on demographic aging and rising life expectancy indicate that annual global incidence will approximately double between 2020 and 2040, from 1.4 million to 2.9 million new cases, with the steepest increases expected in low- and middle-income countries, where changing age structures and increasing life expectancy will drive the majority of the surge.

Prostate cancer arises from the malignant transformation of the glandular epithelium of the prostate, with acinar adenocarcinoma accounting for roughly 95% of all cases, the remaining fraction comprises ductal adenocarcinoma, neuroendocrine and small cell carcinomas, urothelial carcinoma, and rarer histological subtypes. Anatomically, approximately 70–75% of prostatic carcinomas develop in the peripheral zone, 20–25% in the transition zone, and 5–10% in the central zone, a distribution that strongly influences both detection and clinical presentation. In contrast to most solid tumors, the dominant risk factors are non-modifiable: advancing age, with incidence rising steeply after the sixth decade; African ancestry, associated with roughly double the incidence observed in men of European heritage and with disproportionately higher mortality; and family history, which confers a two to threefold increase in risk. An inherited component is identified in 5–15% of patients, most often associated with germline mutations in BRCA2, BRCA1, HOXB13, ATM, CHEK2, or mismatch repair genes, with BRCA2 carrying the strongest association with aggressive, early-onset disease. Modifiable contributions are comparatively weak, and obesity and smoking correlate more consistently with fatal than with indolent disease.

Clinically, prostate cancer is dangerous not because it is uniformly lethal, but because the minority of tumors destined to kill are difficult to separate from the large majority that will not. The gland lies deep in the pelvis beneath the bladder, and the peripheral zone - where most carcinomas originate - sits furthest from the urethra, so early tumors produce no obstructive symptoms whatsoever. The urinary complaints men most readily associate with the prostate, including hesitancy, weak stream, and nocturia, arise predominantly from benign hyperplasia of the transition zone, and their presence or absence is a poor guide to malignancy. Serum PSA permits detection before symptoms appear, but it is organ-specific rather than cancer-specific, elevated equally by hyperplasia, inflammation, and instrumentation, producing both overdiagnosis of indolent disease and false reassurance in aggressive cases. By the time classical signs emerge, such as bone pain, pathological fracture, spinal cord compression, hematuria, obstructive uropathy, or anemia, the tumor has usually disseminated. Metastatic spread follows a characteristic anatomical logic: bone is the dominant first site in the large majority of metastatic cases, with the axial skeleton - lumbar spine, pelvis, ribs, and proximal femur - preferentially involved, reached in part through the valveless vertebral venous plexus of Batson, which permits retrograde flow bypassing the pulmonary filter. Regional lymphatic spread proceeds to the obturator and iliac chains before the retroperitoneum, while visceral deposits in liver and lung appear later and correlate with aggressive or neuroendocrine-differentiated variants. Unusually among solid tumors, prostatic bone metastases are predominantly osteoblastic, producing sclerotic lesions that are structurally disorganized and fracture-prone despite their increased radiographic density.

3-5 times a day.